» Articles » PMID: 34962017

Nanomedicine Targets Iron Metabolism for Cancer Therapy

Overview
Journal Cancer Sci
Specialty Oncology
Date 2021 Dec 28
PMID 34962017
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Iron is an essential element for cell proliferation and homeostasis by engaging in cell metabolism including DNA synthesis, cell cycle, and redox cycling; however, iron overload could contribute to tumor initiation, proliferation, metastasis, and angiogenesis. Therefore, manipulating iron metabolisms, such as using iron chelators, transferrin receptor 1 (TFR1) Abs, and cytotoxic ligands conjugated to transferrin, has become a considerable strategy for cancer therapy. However, there remain major limitations for potential translation to the clinic based on the regulation of iron metabolism in cancer treatment. Nanotechnology has made great advances for cancer treatment by improving the therapeutic potential and lowering the side-effects of the proved drugs and those under various stages of development. Early studies that combined nanotechnology with therapeutic means for the regulation of iron metabolism have shown certain promise for developing specific treatment options based on the intervention of cancer iron acquisition, transportation, and utilization. In this review, we summarize the current understanding of iron metabolism involved in cancer and review the recent advances in iron-regulatory nanotherapeutics for improved cancer therapy. We also envision the future development of nanotherapeutics for improved treatment for certain types of cancers.

Citing Articles

Iron metabolism in non-alcoholic fatty liver disease: A promising therapeutic target.

Chen H Liver Res. 2025; 6(4):203-213.

PMID: 39957910 PMC: 11791839. DOI: 10.1016/j.livres.2022.09.003.


LDH Isoenzyme and GAA-BSA Nanoparticles: A Novel Therapy Approach for Proneural Subtype Glioblastoma Multiforme.

Yang M, Han X, Li H, Du F, Feng C, Gong A J Cancer. 2025; 16(4):1101-1117.

PMID: 39895794 PMC: 11786042. DOI: 10.7150/jca.98452.


Tumoroid-On-a-Plate (ToP): Physiologically Relevant Cancer Model Generation and Therapeutic Screening.

Seyfoori A, Liu K, Caruncho H, Walter P, Akbari M Adv Healthc Mater. 2024; 14(1):e2402060.

PMID: 39538973 PMC: 11694087. DOI: 10.1002/adhm.202402060.


Phytosynthesis, Characterization, Phenolic and Biological Evaluation of -Based Zn and Fe Nanoparticles Utilizing Two Different Extraction Techniques.

El-Fitiany R, Alblooshi A, Samadi A, Khasawneh M Int J Nanomedicine. 2024; 19:11003-11021.

PMID: 39502631 PMC: 11537101. DOI: 10.2147/IJN.S480716.


Preparation of transferrin-modified IR820-loaded liposomes and its effect on photodynamic therapy of breast cancer.

Di Z, Shuhe Z, Baoding S, Yihan Z, Guangming J Discov Oncol. 2024; 15(1):611.

PMID: 39487890 PMC: 11531457. DOI: 10.1007/s12672-024-01486-z.


References
1.
Adam A, Bornhovd C, Prokisch H, Neupert W, Hell K . The Nfs1 interacting protein Isd11 has an essential role in Fe/S cluster biogenesis in mitochondria. EMBO J. 2005; 25(1):174-83. PMC: 1356348. DOI: 10.1038/sj.emboj.7600905. View

2.
Huo M, Wang L, Chen Y, Shi J . Tumor-selective catalytic nanomedicine by nanocatalyst delivery. Nat Commun. 2017; 8(1):357. PMC: 5572465. DOI: 10.1038/s41467-017-00424-8. View

3.
Corce V, Gouin S, Renaud S, Gaboriau F, Deniaud D . Recent advances in cancer treatment by iron chelators. Bioorg Med Chem Lett. 2015; 26(2):251-256. DOI: 10.1016/j.bmcl.2015.11.094. View

4.
Kang H, Han M, Xue J, Baek Y, Chang J, Hu S . Renal clearable nanochelators for iron overload therapy. Nat Commun. 2019; 10(1):5134. PMC: 6853917. DOI: 10.1038/s41467-019-13143-z. View

5.
Alim I, Caulfield J, Chen Y, Swarup V, Geschwind D, Ivanova E . Selenium Drives a Transcriptional Adaptive Program to Block Ferroptosis and Treat Stroke. Cell. 2019; 177(5):1262-1279.e25. DOI: 10.1016/j.cell.2019.03.032. View